Nucleic Acid-based Technologies in Therapy of Malignant Gliomas

Author(s): Monika Piwecka, Katarzyna Rolle, Eliza Wyszko, Ryszard Zukiel, Stanislaw Nowak, Miroslawa Z. Barciszewska, Jan. Barciszewski

Journal Name: Current Pharmaceutical Biotechnology

Volume 12 , Issue 11 , 2011

Become EABM
Become Reviewer
Call for Editor


Malignant gliomas are the deadliest brain tumors, which are characterized by highly invasive growth, a rampant genetic instability and intense resistance to apoptosis. Such an aggressive behavior of malignant gliomas is reflected in the resistance to chemo- and radiotherapy and weak prognosis in spite of cytoreduction through surgery. Brain tumors preferentially express a number of specific protein and RNA markers, that may be exploited as potential therapeutic targets in design of the new treatment modalities based on nucleic acids. For almost three decades, a possibility to apply DNA and RNA molecules as anticancer therapeutics have been studied. A variety of antisense oligonucleotides, ribozymes, DNAzymes, and aptamers can be designed to trigger the sequence-specific inhibition of particular mRNA of interest. RNA interference (RNAi) is the latest and the most promising technique in the long line of nucleic acid-based therapeutic technologies. Recently, we designed and implemented the experimental therapy of patients suffering from malignant brain tumors based on application of double-stranded RNA (dsRNA) specific for tenascin-C (TN-C) mRNA. That therapeutic agent, called ATN-RNA, induces RNAi pathway to inhibit the synthesis of TN-C, the extracellular matrix protein which is highly overexpressed in brain tumor tissue. In the chapter specific problems of application of nucleic acid-based technologies in glioma tumors treatment will be discussed.

Keywords: Glioblastoma multiforme, GBM, brain tumors, malignant gliomas, brain tumor therapy, RNA interference, Tenascin-C, ATN-RNA, antisense oligonucleotides, nucleic acid-based therapeutic technologies, cellular polymorphism, vascular thrombosis, tumor cells, heterogeneous nature, actin-binding molecules

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1805 - 1822]
Pages: 18
DOI: 10.2174/138920111798377067
Price: $65

Article Metrics

PDF: 20